OPTN News and Press, OptiNose Inc. From 02/28/23

YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, befo...

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administ...

Pharmaceutical company Optinose ( NASDAQ: OPTN ) said Peter Miller has stepped down as CEO and board member, and Ramy Mahmoud is appointed a successor with immediate effect. Mahmoud has been the company's president and COO since 2010. Separately, the company reitera...

YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mah...

Summary OptiNose's current treatment of chronic sinusitis is both effective at treating this condition and bringing revenues. Their negative EBITDA and equity combined with their low cash pose a major flag of caution for investors. Their current situation will make or break the comp...

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently th...

Optinose ( NASDAQ: OPTN ) has announced that Michele Janis, Acting CFO, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting CFO until her departure on December 30, 2022. Anthony Krick, Vice President, Controll...

YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportuni...

$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis Revised Note Purchase Agreement Extends Start of Amortization to September 2025 YARDLEY, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Op...

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and war...